CCHT has formed the development platform for three industries including ge
Changchun High-tech Industry, founded in 1993 and was listed at Shenzhen Stock Exchange in 1996. It has established its industrial orientation with the biopharmaceutical industry as the primary and real estate industry as the supplement, has formed the development platform for three industries including genetic engineering pharmaceuticals, biological vaccines and modern traditional Chinese medicine. The main shareholders are Changchun Gaoxin Chaoda Investment Company, Jin Lei and Lin Dianhai. The company's direct and indirect competitors include Yongan Pharmaceutical, Da An Gene and Beijing Genomics Institute.
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
ResearchTechnology, Healthcare, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchIndustrials, Financials, Automotive
Tech for Global, Globalization Footprints of the Established and the New
Genetron Health's Self-Developed Mutation Capsule Differentiates It from Others
Since the outbreak of COVID-19, new public health systems and advanced biotechnology have been swiftly hyped up. Genetron Health has been able to generate a surging revenue in these special social circumstances.
May 26, 2021 05:17 AM
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM